A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

Part of paid clinical trials in Glendale, California.

Sponsor
AstraZeneca
Study ID
NCT07513571
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • AZD4954 — DRUG
    AZD4954 will be administered orally.
  • Laroprovstat — DRUG
    Laroprovstat will be administered orally.

Study Details

The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.

Key Dates

First listed
Apr 7, 2026
Start date
Apr 10, 2026
Status verified
Jul 2026
Primary completion
Jul 8, 2026
Completion
Jul 8, 2026

Study Design

Enrollment
31 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Treatment Sequence AC
    Participant will receive single dose of AZD4954 alone (Treatment A) followed by single doses of laroprovstat+AZD4954 (Treatment C).
  • Experimental: Cohort 2: Treatment Sequence BC
    Participant will receive single dose of laroprovstat alone (Treatment B) followed by single doses of laroprovstat+AZD4954 (Treatment C).

Primary Outcome Measure

Area under concentration time curve from time 0 to infinity (AUCinf) of AZD4954 [ Time Frame: Cohort 1: Day 1 to Day 41 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteGlendaleCalifornia91206-

Related Studies